Advertisement
Organisation › Details
BRAIN Biotech AG
BRAIN Biotech AG (“BRAIN”) is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products – BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success. BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group. As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly. Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394). *
Start | 2021-05-12 renamed before | |
Group | BRAIN Biotech (Group) | |
Predecessor | BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN) | |
Industry | BIOTECH | |
Industry 2 | WHITE BIOTECHNOLOGY | |
Person | Moelker, Adriaan (BRAIN 202002– CEO before Flint Group + AB Enzymes + Genencor + DSM) | |
Person 2 | Krohn, Michael (BRAIN Biotech 202210– RnD Head of Akribion Genomics before RnD Head of BRAIN Biotech AG) | |
Region | Zwingenberg | |
Country | Germany | |
Street | 34-36 Darmstädter Str. | |
City | 64673 Zwingenberg | |
Address record changed: 2022-09-17 | ||
Basic data | Employees | D: 101 to 500 (2022-09-30) |
Currency | EUR | |
Annual sales | 49,509,000 (revenues, consolidated (2021/22) 2022-09-30) | |
Profit | -6,341,000 (2022-09-30) | |
Cash | 8,443,000 (2022-09-30) | |
* Document for »About Section«: BRAIN Biotech AG. (5/30/22). "Press Release: Prof. Dr. Bernhard Hauer Leaves Supervisory Board of BRAIN Biotech AG for personal reasons". Zwingenberg. | ||
Record changed: 2024-09-26 |
Advertisement
More documents for BRAIN Biotech (Group)
- [1] BRAIN Biotech AG. (9/20/24). "Press Release: BRAIN Biotech AG Concludes Major Pharma Compound Transaction Valued up to EUR 128.88 Million from Its BioIncubator". Zwingenberg....
- [2] BRAIN Biotech AG. (8/22/24). "Press Release: BRAIN Biotech AG Launches the Innovative Technology Platform MetXtra Enabling Unique Enzyme Solutions". Zwingenberg....
- [3] BRAIN Biotech AG. (5/29/24). "Press Release: BRAIN Biotech AG Announces the Appointment of Erik de Vries as Senior Business Development Director Enzymes". Zwingenberg & Greifswald....
- [4] BRAIN Biotech AG. (2/29/24). "Press Release: BRAIN Biotech AG Successfully Placed EUR 5.0 Million Convertible Bond for the Financing of Further Growth Initiatives [Not for US, AU, et al.]". Zwingenberg....
- [5] BRAIN Biotech AG. (9/14/23). "Press Release: BRAIN Biotech AG’s Akribion Genomics Technology Receives Patent Approval for Its Groundbreaking Nuclease G-dase E". Zwingenberg....
- [6] BRAIN Biotech AG. (2/8/23). "Press Release: Structural Proteins for the Development of Sustainable Materials. BRAIN Biotech and AMSilk Cooperate to Develop High-performance Bio-based Protein Fibers". Zwingenberg & Neuried....
- [7] BRAIN Biotech AG. (9/27/22). "Press Release: Change in the Executive Management Board of BRAIN Biotech AG, Genome Editing Activities Established Under the Akribion Genomics brand". Zwingenberg....
- [8] BRAIN Biotech AG. (5/30/22). "Press Release: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting". Zwingenberg....
- [9] BRAIN Biotech AG. (5/30/22). "Press Release: Prof. Dr. Bernhard Hauer Leaves Supervisory Board of BRAIN Biotech AG for personal reasons". Zwingenberg....
- [10] Enzymicals AG. (3/8/22). "Press Release: Enzymicals AG Board of Supervisors Appoints New Management with Dr. Erik de Vries as CEO". Greifswald....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top